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Research
More than half the insecticides used today in
the United States are organophosphate com-
pounds. These pesticides are preferred because
of their low toxicity and low cost of manufac-
ture. Multiple uses of these pesticides have led
to an increase in environmental and occupa-
tional exposures, especially in manufacturing,
agriculture, greenhouse/nursery employees,
veterinarians, groomers, and teachers [Agency
for Toxic Substances and Disease Registry
(ATSDR) 2001]. Environmental exposures in
many cases result from the community con-
trol of mosquito populations in large cities
such as New York, New York, and Los
Angeles, California, in an effort to decrease
the incidence of diseases such as West Nile
virus [New York City Department of Health
(NYCDH) 1999; Windham et al. 1998].
Toxicity of all organophosphate pesticides
occurs through the inhibition of acetyl-
cholinesterase by phosphorylation, resulting in
an accumulation of acetylcholine (Bolognesi
2003). This accumulation leads to pesticide
illness, which can be avoided if treatment is
given soon after pesticide exposure (Saxena
et al. 1997). Pesticide exposure symptoms are
similar to those of common illnesses such as
inﬂuenza or upper respiratory infection, mak-
ing pesticide illness difficult to diagnose in
most cases. Analysis of gene expression alter-
ations after common illnesses is limited. Early
diagnosis of pesticide illness could be aided
with the discovery of biomarkers of exposure
to organophosphate pesticides.
Biomarkers of exposure for speciﬁc pesti-
cides or pesticide classes can be determined in
part with gene expression profiling. Gene
expression signatures for pesticides with
unknown side effects have recently been sug-
gested as a means of deﬁning pesticide action
and discovering pesticide alternatives (Duke
et al. 2003). These signatures would allow a
comparison between pesticides and known
carcinogens or genotoxic agents to assist in
conclusively determining the effect of
organophosphate pesticide exposure in human
populations.
This study examines the gene expression
profile of malathion, a widely used organo-
phosphate pesticide with a potential for a
high degree of environmental and occupa-
tional exposure in humans. In vivo animal
studies of malathion exposure have shown
positive results of chromosomal damage [U.S.
Environmental Protection Agency (U.S.
EPA) 2000a], although previous research on
malathion to show genotoxicity and/or car-
cinogenicity has been inconclusive in humans
(Windham et al. 1998). Most of these studies
are generally performed on pesticide applica-
tors, making it difﬁcult to analyze exposure to
just one pesticide (Titenko-Holland et al.
1997); however, Blasiak et al. (1999) analyzed
the effect of malathion exposure alone on
human peripheral blood lymphocytes. Their
in vitro analysis indicated that malathion’s
two main metabolites, malaoxon and iso-
malathion, did in fact act as genotoxic com-
pounds after only 1 hr of exposure, whereas
pure-grade malathion had no such effect.
These two metabolites have been found as
contaminants in the technical-grade mala-
thion commonly used today. To conﬁrm and
extend these results, further in vitro studies
are needed.
The present study, using malathion with
98.6% purity, was designed to analyze this
pesticide’s biologic activity at the gene expres-
sion level. The concentration used is equiva-
lent to 0.2 mg/0.1 m3, which is 10-fold less
than the no observed adverse effect level for
acute exposures in humans at which early
signs of malathion-related illness have been
reported (ATSDR 2001). Gene expression
was measured by microarrays after exposure to
malathion for both 6 and 24 hr, allowing
more time for metabolite formation in the
model system used. The model system was
chosen partly for its ease of access to normal
tissues as well as its ease of use. This system,
normal human mammary epithelial cells
(NHMECs), was selected not only for analysis
of gene expression signatures after malathion
exposure but also to assess interindividual vari-
ation in response to this pesticide. Although
the use of immortalized cell lines related to
neurologic and/or respiratory response may in
some ways seem a more viable model, these
types of cell lines would not yield any infor-
mation about interindividual variation of
response. Variable response in human cell
strains may lead to the discovery of candidate
biomarkers related to at-risk worker popu-
lations, whereas the gene expression profile
generally gives the potential to support geno-
toxicity and carcinogenicity of malathion.
Address correspondence to A. Weston, Molecular
Epidemiology Team, Toxicology and Molecular
Biology Branch, Health Effects Laboratory Division,
NIOSH, CDC, 1095 Willowdale Rd., Mail Stop
L-3014, Morgantown, WV 26505-2888 USA.
Telephone: (304) 285-6221. Fax: (304) 285-5708.
E-mail: agw8@cdc.gov
We thank M. Toraason and L. Sargent for their
careful review of the manuscript. We also thank
G. Johnson for her invaluable assistance in format-
ting and editing the manuscript. 
The authors declare they have no competing
ﬁnancial interests.
Received 7 June 2004; accepted 10 May 2005.
Differential Gene Expression in Normal Human Mammary Epithelial Cells
Treated with Malathion Monitored by DNA Microarrays
Maureen R. Gwinn,1 Diana L. Whipkey,2 Lora B. Tennant,2 and Ainsley Weston2
1Pathology and Physiology Branch, and 2Molecular Epidemiology Team, Toxicology and Molecular Biology Branch, Health Effects
Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown,
West Virginia, USA
Organophosphate pesticides are a major source of occupational exposure in the United States.
Moreover, malathion has been sprayed over major urban populations in an effort to control mosquitoes
carrying West Nile virus. Previous research, reviewed by the U.S. Environmental Protection Agency, on
the genotoxicity and carcinogenicity of malathion has been inconclusive, although malathion is a
known endocrine disruptor. Here, interindividual variations and commonality of gene expression sig-
natures have been studied in normal human mammary epithelial cells from four women undergoing
reduction mammoplasty. The cell strains were obtained from the discarded tissues through the
Cooperative Human Tissue Network (sponsors: National Cancer Institute and National Disease
Research Interchange). Interindividual variation of gene expression patterns in response to malathion
was observed in various clustering patterns for the four cell strains. Further clustering identiﬁed three
genes with increased expression after treatment in all four cell strains. These genes were two aldo–keto
reductases (AKR1C1 and AKR1C2) and an estrogen-responsive gene (EBBP). Decreased expression of
six RNA species was seen at various time points in all cell strains analyzed: plasminogen activator
(PLAT), centromere protein F (CPF), replication factor C (RFC3), thymidylate synthetase (TYMS), a
putative mitotic checkpoint kinase (BUB1), and a gene of unknown function (GenBank accession no.
AI859865). Expression changes in all these genes, detected by DNA microarrays, have been veriﬁed
by real-time polymerase chain reaction. Differential changes in expression of these genes may yield
biomarkers that provide insight into interindividual variation in malathion toxicity. Key words:
DNA microarray, gene expression, malathion, pesticide, toxicology. Environ Health Perspect
113:1046–1051 (2005). doi:10.1289/ehp.7311 available via http://dx.doi.org/ [Online 10 May 2005]Further research focusing on the response
of any biomarkers discovered in this model
could then be performed in cell lines related to
clinical end points of malathion exposure.
Materials and Methods
Cell culture. Primary NHMECs were derived
from tissues salvaged at reduction mammoplasty
and obtained through the Cooperative Human
Tissue Network (National Cancer Institute
and National Disease Research Interchange,
Bethesda, MD). Development and characteri-
zation of cell strains were achieved using stan-
dard methods (Stampfer 1985). Cells were
grown in mammary epithelium growth media
(MEGM; Clonetics, Cambrex, Pittsburgh, PA)
at 37°C and 5% CO2.
Malathion treatment. Treatment was
performed on cells in passage six that were
70% confluent. The malathion used was
98.6% pure, based on chemical analysis from
the company (Sigma-Aldrich, St. Louis,
MO). Preliminary studies analyzed a range of
malathion concentrations (25–100 µg/mL)
and time points (0–24 hr) and showed mini-
mal toxicity at 24 hr with a final concentra-
tion of 50 µg/mL. Cells were treated by
diluting the stock malathion/dimethyl sulfox-
ide (DMSO) mixture in media and adding
this solution to aspirated cells, allowing even
exposure to all cells. DMSO (0.001%) alone
was used as a vehicle control. All treatments
were performed in triplicate. At the end of the
treatment period, cells were removed for
RNA isolation. Cell viability was determined
by trypan blue exclusion assay.
Microarray analysis. Microarray analysis
was performed in triplicate using U133A
high-density oligonucleotide microarrays
(Affymetrix, Santa Clara, CA). Protocols were
followed from Affymetrix GeneChip Expression
Analysis Technical Manual (Affymetrix, 2001).
Briefly, RNA was isolated from cells with
Trizol (Gibco, Grand Island, NY) followed
by puriﬁcation with RNEasy Mini Kit (Qiagen,
Valencia, CA). Spectrophotometer measure-
ments were required to give a 260/280 ratio
of 1.9–2.1 for use in microarray analysis.
Double-stranded cDNA was then synthesized
from total RNA (Superscript Choice System;
Invitrogen, Carlsbad, CA). An in vitro tran-
scription reaction (Enzo, Farmingdale, NY)
was then performed to produce biotin-labeled
cRNA from the cDNA. Excess biotinylated
dUTPs were removed by RNEasy Mini Kit
before being fragmented and added to a
hybridization cocktail including eukaryotic
hybridization controls (Affymetrix), bovine
serum albumin and herring sperm DNA
(Gibco) and biotinylated anti-streptavidin
antibody (Vector Laboratories, Burlingame,
CA). Hybridization on microarrays was per-
formed for 16 hr at 45°C in a gene chip
hybridization oven with rocker (Affymetrix).
Microarrays were washed and stained using the
protocol as described in the Affymetrix
GeneChip Expression Analysis Technical Manual
(Affymetrix, 2001) with the GeneChip
Fluidics Station 400 (Affymetrix). Arrays were
then scanned with an Affymetrix scanner
(Hewlett Packard, Palo Alto, CA). Expression
profiles were analyzed using Microarray
Suite 5.0, MicroDB 3.0, and Data Mining
Tool 3.0 (Affymetrix). Affymetrix arrays are
produced using multiple 25-mer oligonu-
cleotides (11–20 per target gene). Each
oligonucleotide is created to match the selected
region of the target gene (perfect match, PM),
and a similar oligonucleotide is created altered
in the 13th position to control for nonspeciﬁc
binding (mismatch, MM). Results are given in
signal intensities with a p-value determined
from perfect match/mismatch (PM/MM)
intensities by Tukey’s biweight analysis. The
average intensity values obtained for each treat-
ment time point were compared with those of
the control treatment (DMSO) to determine
the effect of the malathion exposure. Signal log
ratio (SLR) was determined by comparison of
the signal intensities for the baseline (vehicle
control) and the treatment array. An SLR of 0
represents no change in gene expression as a
result of malathion exposure. An SLR of 1 is
equivalent to a 2-fold change between the
treatment and control. The results described
here are representative of triplicates, with an
average percent variability between duplicate
arrays of 1.5%. The average of intensity values
obtained for each treatment time point was
compared with that of the control treatment
(DMSO) to determine the effect of the
malathion exposure. Signiﬁcance of comparison
was determined by t-test values of p ≤ 0.05.
Only relative changes ≥ 0.6 SLR were consid-
ered a signiﬁcant change as a result of exposure.
Gene chip analysis was performed by self-orga-
nizing map (SOM) clustering, focusing on
genes with a detection p-value of ≤0.05 at one
or more time points.
Real-time polymerase chain reaction
(RT-PCR) analysis. cDNA synthesized from
each sample as in the Affymetrix analysis
(Invitrogen) was used in a one-step real-time
polymerase chain reaction (RT-PCR) analysis
reaction. Analysis was performed in duplicate
on the ABI 7700 cycler, with the SYBR Green
Master Mix (ABI; Applied Biosystems, Foster
City, CA). Primers were designed using Primer
Express (ABI) to yield unique fragments for
each gene under study. Reactions were set up
following recommended protocols using
100 pmol of each primer (Sigma-Genosys, The
Woodlands, TX) and approximately 60 ng of
template per reaction. Reactions were per-
formed in duplicate for each sample for
40 cycles (95°C/15 sec denaturing step;
60°C/1 min annealing/extension step). Fold
change was determined based on average cycle
threshold (CT) values for all duplicates and
converted to SLR.
Gene expression profile after malathion exposure
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Figure 1. Gene expression patterns for four representative genes after exposure to malathion for 6 and 24 hr
for both microarray and RT-PCR analysis: (A) aldo–keto reductase 1C1; (B) estrogen-responsive b-box pro-
tein; (C) thymidylate synthetase; (D) replication factor C. Results for all are shown as cell strain versus SLR
for each of four cell strains. Results are from comparison of averaged signal intensities for both treated
and control. 
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Trypan blue exclusion test. Trypan blue was
used to analyze toxicity by measuring cell via-
bility for each cell strain for each treatment.
The results showed a range of viability of
92–97% at all time points for all strains ana-
lyzed (results not shown).
DNA microarray. Microarray analysis
focused on genes altered by 1.5-fold change
(±0.6 SLR) with a p-value ≤ 0.05, which
yielded varying numbers of genes altered
for each cell strain (strain 1: 674 increased,
408 decreased; strain 2: 382 increased, 411
decreased; strain 3: 1,058 increased, 1,019
decreased; strain 4: 714 increased, 665
decreased). The ±0.6 SLR was selected arbi-
trarily to include most statistically signiﬁcant
gene expression changes. Comparisons
between cell strains at all time points yielded a
large number of genes (13,712) that were used
as a base for further analysis by clustering.
SOM clustering for all cell strains found only
three genes increased in four cell strains, and
only six were found to be decreased. The three
genes increased in all cell strains included two
aldo–keto reductases [2α-hydroxysteroid
dehydrogenase (AKR1C1) and 3α-hydroxy-
steroid dehydrogenase (AKR1C2)] and an
estrogen-responsive gene (EBBP). The genes
decreased included plasminogen activator
(PLAT), centromere protein F (CPF), replica-
tion factor C (RFC3), thymidylate synthetase
(TYMS), putative mitotic checkpoint kinase
(BUB1), and a gene of unknown function
(GenBank accession no. AI859865; http://
www.ncbi.nlm.nih.gov/GenBank). Four
examples of these are shown in Figure 1.
Further SOM analysis looked at genes altered
in three of the four cell strains analyzed,
including another aldo–keto reductase,
pseudo-chlordecone reductase (AKR1C4).
Those decreased in three of four cell strains
included cyclinA2 (CCNA2), cyclin-dependent
kinase inhibitor (p16INK4A), and cell division
control 20 (CDC20) (Table 1). The full list of
genes altered in each cell strain can be found in
the publication by Gwinn et al. (2004b),
including genes found to be altered in at least
two of four cell strains analyzed. Venn dia-
grams show the breakdown of these gene
expression patterns (Figure 2A,B). Examples
from this list are Hsp40 (GenBank accession
no. BC095400) and stress-associated endo-
plasmic reticulum protein (GenBank accession
no. BF747267), both involved in stress
response and increased after malathion expo-
sure. Cytochrome b5 reductase (GenBank
accession no. AF169802) is also increased after
exposure to malathion, although this gene is
involved in xenobiotic metabolism similar to
the aldo–keto reductase gene family members
increased in all cell strains analyzed. Those
decreased in at least two cell strains include
genes involved in protein modification and
Gwinn et al.
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Table 1. Genes altered after exposure to malathion (SLR).a
6-hr microarray 24-hr microarray
Gene symbol (accession no.)b SLR p-Value RT-PCR SLR p-Value RT-PCR
AKR1C1 (M86609)
1 3.69 0.30 2.94 4.22 0.14 5.86
2 1.23 0.07 3.32 5.93 0.00* 6.60
3 2.47 0.00* 2.35 5.01 0.01* 4.58
4 1.82 0.01* 3.05 3.92 0.00* 5.65
AKR1C2 (U05861)
1 3.55 0.31 4.13 4.18 0.14 4.78
2 1.92 0.01* –0.54 6.08 0.01* 0.24
3 3.09 0.00* 1.88 5.56 0.00* 4.12
4 1.39 0.08 1.33 3.36 0.00* 3.63
EBBP (NM_006470)
1 1.69 0.01* 6.07 1.85 0.03* 2.33
2 4.44 0.01* 1.36 1.65 0.00* 2.12
3 1.46 0.06 1.48 1.61 0.03* 2.47
4 1.51 0.14 3.05 1.76 0.02* 3.50
Chlordecone reductase (NM_001818)
1 3.42 0.33 0.80 3.96 0.15 3.06
2 0.96 0.03* 3.66 5.74 0.04* 3.74
3 1.82 0.01* 2.03 4.81 0.00* 4.69
4 1.71 0.00* 2.56 3.57 0.02* 4.76
BUB1 (NM_001211)
1 –1.36 0.23 0.10 –1.91 0.17 1.25
2 0.96 0.06 1.48 –2.19 0.08 –3.47
3 –1.99 0.02* –1.53 –1.90 0.03* –1.89
4 0.14 0.19 –0.09 –0.75 0.01* –0.54
TYMS (NM_001071)
1 –1.15 0.03* –0.54 –1.66 0.01* –3.19
2 0.74 0.36 2.19 –2.14 0.04* –3.84
3 –0.76 0.09 –1.49 –2.17 0.00* –3.40
4 0.11 0.21 0.90 –0.99 0.00* 0.31
PLAT (NM_000930)
1 –2.06 0.00* 2.57 –2.25 0.00* –0.56
2 0.23 0.81 –1.15 –1.53 0.20 0.87
3 –2.09 0.00* –1.50 –1.96 0.00* –2.77
4 –0.74 0.04* –0.94 –1.34 0.01* –0.69
RFC3 (BC000149)
1 –0.39 0.21 0.13 –2.11 0.02* –3.24
2 –0.06 0.25 –0.84 –1.41 0.65 –3.32
3 –1.23 0.01* –1.72 –1.93 0.01* –4.41
4 0.18 0.48 1.14 –0.80 0.01* 0.89
Unknown (AI859865)
1 0.02 0.65 NA –2.97 0.00* NA
2 –1.26 0.05* NA –1.61 0.04* NA
3 –1.29 0.07 –2.23 –1.72 0.05* –1.86
4 0.33 0.20 1.30 –1.11 0.05* 2.67
CDC20 (NM_001255)
1 –4.14 0.00* 0.55 –2.57 0.00* –2.64
2 0.61 0.01* 0.31 –1.94 0.00* –4.06
3 –2.05 0.01* –2.25 –3.50 0.01* –5.06
4 0.12 0.56 –0.51 –0.61 0.04* –0.79
CYCLINA2 (NM_001237)
1 –0.48 0.06 0.81 –1.70 0.00* –0.84
2 0.41 0.39 –0.97 –1.51 0.62 –5.06
3 –1.12 0.06 –0.89 –3.72 0.02* –5.64
4 –0.03 0.50 0.30 –2.50 0.01* 1.94
CPF (NM_016343)
1 –3.39 0.06 4.12 –2.11 0.07 0.96
2 –0.45 0.60 0.41 –2.12 0.17 –5.64
3 –2.03 0.03* 0.21 –3.88 0.02* –5.64
4 0.41 0.00* 0.14 –1.58 0.00* –0.84
p16 (AF115544)
1 –1.88 0.50 1.79 –2.53 0.03* 0.77
2 –1.18 0.02* –2.06 –1.55 0.17 –2.40
3 –2.51 0.17 0.11 –4.15 0.05* –1.47
4 0.50 0.18 0.29 –0.12 0.15 0.06
NA, not applicable. 
aData are gene expression patterns for select genes after malathion exposure for both 6 and 24 hr for both microarray
and RT-PCR analysis. Genes are listed for each cell strain (1–4) with columns showing SLR for microarray analysis with
the associated p-value along with the RT-PCR result for each time point. Statistical analysis was performed by t-test
using signal intensity values for triplicate analyses with Data Mining Tool 3.0 (Affymetrix). bFrom GenBank (http://www.
ncbi.nlm.nih.gov/GenBank). *p ≤ 0.05.cyclin degradation [ubiquitin carrier protein
E2C (GenBank accession no. NM_00799)
and ubiquitin-conjugating enzyme E2-EPF
(GenBank accession no. NG_001583),
respectively] along with genes for structural
proteins α- and β-tubulin (GenBank accession
nos. AF141347, AI860746). These genes
along with others found on this list, because
they are altered in only two of four cell strains
analyzed, represent the interindividual varia-
tion found in response to malathion exposure.
RT-PCR. RT-PCR results conﬁrmed those
found by microarray analysis for genes ana-
lyzed, with a Pearson’s correlation analysis r2 of
0.70 (p ≤ 0.0001). Analysis was performed for
select genes as shown in Table 1, including
genes in Figure 1 showing the comparison
between microarray and RT-PCR results.
Some variability can be seen for some time
points, but the direction of change remains
constant. Variable results include those results
found to have no significant change by
microarray analysis as measured by t-test. Also,
RT-PCR showed increased levels of change in
many cases (TYMS, EBBP, RFC3) most likely
related to the increased speciﬁcity of RT-PCR.
Microarray results unconfirmed by RT-PCR
are most likely related to differences in
sequences used in primer design compared
with those used in probe design on the
microarray. Despite these variations, these
genes were included for discussion purposes
and for inclusion in future studies.
Discussion
In the United States today, organophosphates
make up the major class of pesticides (U.S.
EPA 2003b), yet little is known about their
potential genomic effects. The goal of the pre-
sent study was to compile information on
changes in gene expression proﬁles after expo-
sure to the pesticide malathion. Previous
research to determine the biologic effects of
malathion has been inconclusive (U.S. EPA
2003a). To learn more about malathion’s tox-
icity, microarray analysis was used to analyze
the expression profile of malathion in
NHMECs. NHMECs were selected as the
model system because of the availability of
normal tissue, which allows analysis of both
the general effects of exposure and those
related to interindividual differences.
Similar gene expression alterations in
response to malathion exposure were found in
all cell strains for nine genes: a) aldo–keto
reductase 1 (AKR1C1), b) aldo–keto reduc-
tase 2 (AKR1C2), c) an estrogen-responsive
gene (EBBP), d) plasminogen activator (PLAT),
e) centromere protein F (CPF), f) replication
factor C (RFC3), g) thymidylate synthetase
(TYMS), h) putative mitotic checkpoint kinase
(BUB1), and i) a gene of unknown function
(AI859865). Of these, those increased (a–c) are
potentially involved in carcinogen and steroid
metabolism, whereas some of those decreased
are associated with DNA replication (e–g) and
cell cycle progression (h). The aldo–keto
reductase gene family members are involved
in the breakdown and eradication of endoge-
nous and exogenous substrates, including
steroids and pesticides. Recent studies have
implicated these genes in the activation of
polycyclic aromatic hydrocarbons, suggesting
a potentiation of carcinogenicity in the pres-
ence of mixed exposures (Palackal et al. 2002;
Penning et al. 1996). Three of the six genes
found to be decreased after malathion exposure
are involved in DNA replication, with altered
expression resulting in cell cycle arrest (Ellison
and Stillman 2003; Testa et al. 1994; Trinh
et al. 2002). The similarities in the known bio-
logic functions of these genes and their rela-
tionship to carcinogenesis as shown by current
literature suggest that exposure to malathion
may increase the possibility of carcinogenesis.
Regardless, these nine genes are a starting point
in the search for a genetic biomarker of expo-
sure to malathion, and perhaps other pesti-
cides. Of the three genes found to be increased,
AKR1C1 and AKR1C2 were also increased
after exposure to a non-organophosphate pesti-
cide, oxythioquinox (Gwinn et al. 2004a).
Therefore, these two genes may be good gen-
eral markers of pesticide exposure, with per-
haps EBBP as a speciﬁc marker for malathion
exposure. Follow-up studies need to be per-
formed on these nine genes, not only in an
increased number of cell strains (in vitro) but
also in an exposed worker population to con-
ﬁrm expression patterns in vivo. Further analy-
sis of an increased number of normal human
cell strains to support these results will show
whether these nine genes are consistently
altered regardless of interindividual variation.
Results from these studies could be used to
select one or two genes as markers in an epi-
demiology study with exposed workers. Ideally,
workers exposed only to malathion could then
be compared with those exposed to a mixture
of pesticides, but this would depend on popu-
lation availability.
Highlighting the importance of inter-
individual variation, three of the four cell strains
showed similar alterations in select genes. Those
genes increased in three of the four strains
include an additional member of the aldo–keto
reductase family, pseudo-chlordecone reduc-
tase. Like those listed above, this gene is
involved in steroid metabolism, as well as
potential carcinogen metabolism (Jez et al.
Gene expression profile after malathion exposure
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Figure 2. Gene expression patterns for all four cell strains shown as Venn diagrams illustrating the interaction in gene numbers for each of four cell strains.
(A) Genes increased in each cell strain and (B) genes decreased in each cell strain are shown. Numbers of genes altered similarly for the major and minor vari-
ants are given outside the diagrams, and numbers of remaining genes are shown within the diagrams. Using genes that were present on at least one array, only
six genes were found to be increased in all four cell strains, and only three genes were found to be decreased in all four cell strains.
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1997; Kawamata et al. 2003). Genes decreased
in three of the four cell strains included three
genes involved in the regulation and progres-
sion of the cell cycle, CDC20, cyclinA2, and
p16INK4a. CDC20 and cyclinA2 are both
involved in the cell’s progression from
metaphase to anaphase, with CDC20 being
necessary to activate the anaphase promoting
complex leading to the degradation of cyclinA2
(Dunican et al. 2002; Yih and Lee 2003). A
decrease in expression of CDC20 would be
expected to lead to an increase in cyclinA2;
however, these cell strains also showed a
decrease of cyclinA2. Whether this decrease is a
result of a feedback inhibition or a result of
malathion’s mechanism is not known. The
third gene, p16INK4a, is also involved in pre-
venting anaphase promotion by disrupting
cyclin D/CDK4 kinase complex. Inactivation
of p16 along with p14 has been associated with
squamous cell carcinoma (Smeds et al. 2002;
van den Boom et al. 2003). Conﬁrmation not
only of these expression pattern alterations but
also of cell cycle alterations as a result of these
alterations would further suggest the role of
malathion exposure in carcinogenesis. Although
no studies have been published to date on chro-
mosomal variations related to malathion expo-
sure, some gene expression changes after
exposure to malathion in this study are similar
to those found in other cell culture models of
chromosomal changes (Geigl et al. 2004;
Waisﬁsz et al. 2002). These include changes in
centromere protein F (GenBank accession no.
NM_016343), replication factor C (GenBank
accession no. BC000149), and p16INK4A
(GenBank accession no. AF115544). Decreases
in expression of these three genes were found in
all four cell strains and may suggest an increase
in chromosome instability.
Interindividual variation as a result of
genetic polymorphisms in genes of interest
would focus on speciﬁc at-risk worker popula-
tions. For example, the four cell strains analyzed
in this study have been genotyped for a variety
of genes, particularly those involved in cell cycle
control and xenobiotic metabolism. Two of the
four strains selected for analysis are hetero-
zygous for an intermediate variant haplotype of
p53, a cell cycle control gene. Molecular
epidemiologic studies have implicated this hap-
lotype of three p53 polymorphisms [the
codon 72 amino acid substitution (R/P); an
intron 3, 16-bp insertion/deletion polymor-
phism; and an intron 6, single nucleotide poly-
morphism (A/G)] in breast cancer (Keshava
et al. 2002; Sjalander et al. 1996; Wang-
Gohrke et al. 1999; Weston et al. 1997) and
other cancer types (Birgander et al. 1995;
Pfeifer et al. 2002; Robles et al. 2002; Wu et al.
2002). Although no biologic mechanism for
the role of this intermediate variant in carcino-
genesis has been deﬁned, several studies associ-
ating this haplotype with cancer support such a
role. Analysis of genes altered only in the strains
expressing this variant indicated three genes
involved in cell cycle control, p53-inducible
protein (GenBank accession no. Hs.50649),
cyclin D1 (GenBank accession no. Hs.82932),
and proliferating cell nuclear antigen (GenBank
accession no. NM_002592), which may further
support an association between malathion
exposure, p53 variant status, and carcinogenesis
(Flatt et al. 2000; Musgrove et al. 1994; Yao
et al. 2002). Further analysis of these genes in
an increased number of cell strains with known
p53 haplotypes to conﬁrm their expression pat-
tern after malathion exposure is needed to con-
firm these results. However, given that this
haplotype is found only in about 10% of the
population, this varied pattern of expression in
key genes in cell cycle control may highlight a
speciﬁc at-risk population.
Searches for similar natural compounds to
replace these potentially disruptive chemicals
can also use gene expression profiles (Duke
et al. 2003). Proﬁle comparisons with that of a
natural pesticide may decrease the need for
organophosphates. Comparison of malathion’s
gene expression proﬁle with that of well-deﬁned
chemicals such as benzo[a]pyrene will yield
important information about malathion’s role
in both genotoxicity and carcinogenicity.
Results of this experiment showed some similar
expression patterns to those in the same cell
strains exposed to benzo[a]pyrene (Keshava
et al. 2005). Although similarities were found
in expression patterns of a few genes, these did
not include key genes such as the cytochrome
P450s. A more focused comparison between
the two expression proﬁles is needed to further
deﬁne similarities and differences between the
two chemicals. Given the neurotoxicity of
organophosphates, comparisons of the response
to malathion and known neurotoxins would
also be of interest using expression proﬁles from
these same cell strains.
Although people are commonly exposed
to pesticides, human exposure is not well
monitored (Bolognesi 2003; ATSDR 2001).
Discovery of genes altered after exposure to
malathion may aid in future epidemiology
studies on pesticide exposures. Gene expres-
sion proﬁling can be used to yield genetic bio-
markers of exposure that, after validation,
could be used in a clinical setting for early
determination of organophosphate exposure,
increasing early treatment of pesticide illness
and thereby increasing the recovery rate of
exposed individuals.
Gene expression profiling in response to
toxic chemicals can be used to seek evidence
for a chemical’s potential toxicity and carcino-
genicity, absent testing in animals. Further,
discovery of genes altered after exposure to pes-
ticides and other chemicals may provide useful
biomarkers for future studies in environmental
and occupational epidemiology.
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